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Abstract
Background: Herpes Simplex Virus (HSV) Genital Ulcer Disease (GUD) is an important public
health problem, whose interaction with HIV results in mutually enhancing epidemics. Conventional
methods for detecting HSV tend to be slow and insensitive. We designed a rapid PCR-based assay
to quantify and type HSV in cervicovaginal lavage (CVL) fluid of subjects attending a Genito-Urinary
Medicine (GUM) clinic. Vaginal swabs, CVL fluid and venous blood were collected. Quantitative
detection of HSV was conducted using real time PCR with HSV specific primers and SYBR Green
I. Fluorogenic TaqMan Minor Groove Binder (MGB) probes designed around a single base
mismatch in the HSV DNA polymerase I gene were used to type HSV in a separate reaction. The
Kalon test was used to detect anti-HSV-2 IgG antibodies in serum. Testing for HIV, other Sexually
Transmitted Infections (STI) and related infections was based on standard clinical and laboratory
methods.
Results: Seventy consecutive GUM clinic attendees were studied. Twenty-seven subjects (39%)
had detectable HSV DNA in CVL fluid; HSV-2 alone was detected in 19 (70%) subjects, HSV-1 alone
was detected in 4 (15%) subjects and both HSV types were detected in 4 (15%) subjects. Eleven
out of 27 subjects (41%) with anti-HSV-2 IgG had detectable HSV-2 DNA in CVL fluid. Seven
subjects (10%) were HIV-positive. Three of seven (43%) HIV-infected subjects and two of five
subjects with GUD (40%) were secreting HSV-2. None of the subjects in whom HSV-1 was
detected had GUD.
Conclusion: Quantitative real-time PCR and Taqman MGB probes specific for HSV-1 or -2 were
used to develop an assay for quantification and typing of HSV. The majority of subjects in which
HSV was detected had low levels of CVL fluid HSV, with no detectable HSV-2 antibodies and were
asymptomatic.
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Background
Genital herpes, which is caused mainly by Herpes Simplex
Virus (HSV) -2 [1] but also by HSV-1 [2] remains a world-
wide problem [3]. The strongest known risk factor for the
heterosexual transmission of Human Immunodeficiency
Virus (HIV) and other Sexually Transmitted Infections
(STI) is Genital Ulcer Disease (GUD) [4]. Over the past
decade, HSV-2 has been identified as the most common
aetiological agent of GUD [5]. Studies of HSV-2 seroprev-
alence have found high rates in African-Americans [6] and
in African populations in Uganda, Zimbabwe, Tanzania,
Central African Republic, South Africa and The Gambia
[7-12]. In The Gambia, HSV-2 seropositivity among
young adults from rural communities was 28% in women
and 5% in men which increased with age [12]. HSV-2
seroprevalence increases with high risk sexual behaviour
[9] and with factors related to polygynous marriage prac-
tices in rural populations [13]. The majority of subjects
infected with HSV-2 are asymptomatic but exhibit sub-
clinical cervicovaginal virus secretion which is thought to
be important in the transmission of HSV-2 [14,15].
Antiviral therapy with acyclovir or valacyclovir, used dur-
ing episodes of primary and recurrent HSV-2 GUD,
reduces both the rate of secretion, and the rate at which
GUD develops [16,17]. These drugs were also found to
reduce the transmission from an infected person to
another susceptible individual [18] and to minimise sub-
clinical HSV-2 genital secretion, preventing the spread of
disease [19]. Resistance to antiviral drugs has been
reported but occurs infrequently [20]. Interventions there-
fore can be helpful in the reduction of disease by prevent-
ing the spread of HSV, which consequently impacts on
HIV transmission. The effectiveness of such interventions
demands rapid, efficient, reliable and type specific assays.
These assays can serve as biological endpoints in deciding
when to administer intervention, monitoring the effec-
tiveness of any current intervention, determining the effi-
cacy of drugs, assessing drug resistance and are useful
research tools in the study of the epidemiology of
transmission.
The discrimination of HSV-1 from HSV-2 was originally
performed using virus culture followed by antibody bind-
ing to type-specific determinants (virus neutralisation)
[21]. The application of molecular methods, such as
restriction fragment length polymorphism (RFLP) analy-
sis of HSV PCR amplicons is thought to provide a reliable
method of typing the virus [21]. Whilst serology based
typing methods target surface exposed epitopes such as
those on glycoprotein C or G, molecular typing has largely
exploited differences between HSV-1 and -2 DNA
polymerase I genes. Archetypal HSV-1 and -2 DNA
polymerase I genes share 93% sequence identity and 82%
amino acid homology. The selection of strain typing pol-
ymorphisms for molecular methods is based on the
sequence information deposited in public databases cou-
pled with the availability of a convenient restriction endo-
nuclease site. This can identify variation at a selected
single nucleotide polymorphism (SNP) site. A rapid SNP
typing method is useful because it can yield information
about the virus population in the affected host popula-
tion. This is of value in classification and in epidemiolog-
ical studies aimed to investigate host-pathogen interplay.
A more efficient method for diagnosis of HSV infection is
to use PCR in real time for detection and quantification.
HSV SNP sub-typing by 'allele' specific fluorogenic probes
offers many advantages over RFLP methods or viral cul-
ture. Amplification of the target DNA, and hybridization
to a fluorogenic probe are conducted in a single PCR and
therefore the chances of possible contamination are min-
imised. The main advantage of real-time detection is the
large dynamic range offered in a quantitative assay cou-
pled to the ability to discriminate between fluorophores
in a multiplex reaction. We selected Taqman probes incor-
porating the minor groove binder (MGB), 1,2-dihydro-
(3H)-pyrrolo [3,2-e] indole-7-carboxylate (CDPI3) [22].
MGB probes offer high sensitivity and accuracy, due to
their short length which increases the sensitivity and sta-
bility of probe-sequence complexes to single base changes
[23]. However, important consideration should be given
to the selection of the SNP under investigation. Recent
work using Eclipse-MGB probes which bind to a highly
polymorphic region of HSV glycoprotein D found that
sequence polymorphisms in the probe binding region
decreased the sensitivity of typing assay [24]. The present
study used assays based on Taqman-MGB probes, to iden-
tify the HSV type in a population of symptomatic and
asymptomatic patients attending a GUM clinic in The
Gambia. The possible role of other co-infections in the
secretion of HSV in CVL fluid and HSV transmission were
investigated.
Results
Study subjects
Seventy subjects included in the study were of median age
27 years (range 17–50). Genital examination revealed
that 5/70 subjects had GUD (four external and one cervi-
cal). Four subjects withheld consent for HIV serology.
There was one known HIV positive patient identified at a
previous Out Patient Department visit. Two further sam-
ples were not tested for HSV-2 IgG (total tested n = 63)
and one sample was not tested for Hepatitis B and
Treponema pallidium (n = 62) because of insufficient sam-
ple volume.
Quantitative analysis of HSV viral load in CVL
Amplification of the HSV DNA and hybridization to a
fluorogenic probe were conducted in different PCRVirology Journal 2005, 2:61 http://www.virologyj.com/content/2/1/61
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reactions. Three µl of extracted template DNA of a 200 µl
eluate prepared from CVL was used. Most samples had
values less than 10 viral copies/PCR reaction but were
positive as indicated by the presence of an amplification
peak of the correct Tm in dissociation or melting curve
analysis plots. The accurate estimation of the quantity of
HSV was expressed as viral copies/ml of CVL. The lower
limit of quantitation of the HSV assay was therefore 335
viral copies/ml cervical lavage fluid. Forty-three samples
had no detectable HSV amplicons. Twenty-seven out of 70
subjects (39%) had HSV detected in CVL fluid. Figure 1.
shows the HSV load in the CVL fluid of these 27 HSV PCR
positive subjects. The distribution is left censored and the
majority of subjects had <335 copies/ml of lavage. HSV
secretion by quantitative real time PCR in positive sub-
jects ranged from < 335 to 10,409,000 viral genome cop-
ies/ml of CVL fluid.
Determination of HSV-1 and -2 types by Taqman-MGB 
probes
Nineteen of the 27 HSV positive subjects (70%) were
identified as HSV-2, 4/27 (15%) were HSV-1 and 4/27
(15%) were positive for both HSV-1 and -2 by HSV probe
specific binding assay. HSV type was confirmed in 7 sam-
ples in which an equivocal typing result was initially
obtained. HSV type was confirmed by repeating the real-
time assay using the Rotorgene 3000 instrument (Corbett
Research Ltd, Sydney, Australia). Sequencing of all PCR
amplicons and reference control strains gave a 100% con-
firmation with that of the probe at the SNP site (Figure 1).
HSV type and serology
Anti HSV-2 IgG antibodies were detected in 29/63 (46%)
subjects, most of whom were not secreting HSV. The sub-
ject with the highest number of HSV-2 viral genome cop-
ies/ml of CVL fluid had no detectable anti HSV-2 IgG. Two
other CVL fluid samples in which high levels of HSV DNA
were detected were typed as HSV-2 and these were positive
for anti HSV-2 IgG antibodies. In total 10/21 subjects in
whom HSV-2 secretion was detected were negative for
HSV-2 antibodies, whilst 11/21 subjects in which HSV-2
secretion was detected were HSV-2 antibody positive. Two
subjects in which HSV-2 secretion was detected were una-
ble to be tested for anti HSV-2 IgG due to insufficient
serum. A single HSV-1 secretion positive subject was pos-
itive for anti HSV-2 IgG and 3 HSV-1 secretion positive
samples were negative for anti HSV-2 IgG antibodies.
Potential risk factors which may be associated with HSV 
cervicovaginal secretion
Possible cofactors for genital HSV infection were exam-
ined (Table 1) but none of these were associated with cur-
rent HSV secretion in CVL fluid. Data in Table 2 further
demonstrates the lack of a relationship between each risk
co-factor and the quantity of HSV present in CVL. Eight-
een (67%) subjects judged to be secreting HSV had < 335
viral copies / ml of CVL fluid. Five of 70 subjects had
GUD, 2 of 5 were currently secreting HSV (HSV-2 by typ-
ing and positive for anti-HSV-2 IgG). Seven of 66 subjects
(11%) were found to be HIV-1 seropositive. Thirty-five
out of 70 (50%) were diagnosed as having Bacterial Vagi-
nosis (BV). Twenty-nine of 70 (41%) subjects had Cand-
ida and Trichomonas vaginalis was found in 7 out of 70
(10%). Eight out of 62 (13%) were positive for Hepatitis
B and 7 out of 70 (10%) were positive for Chlamydia tra-
chomatis pgp3. None of the subjects were diagnosed as
having Neisseria gonorrhoea, or clue cells. Two of 62 (3%)
subjects were diagnosed as T. pallidium infected, neither of
which secreted HSV.
Determination of HSV-1 and -2 types by Tm
The melting temperatures (Tm) of the HSV amplicon
obtained from the dissociation or melting curve plot fol-
lowing amplification and quantification of HSV are
shown in Figure 1. Both positive and control HSV-1 sam-
ples had Tm ranging from 86.6°C to 86.9°C. HSV-2 posi-
tive samples, ranged from 87.0 – 88.0 °C and an example
of the dissociation plot is shown in Figure 2. Dual HSV -1
and -2 infections, confirmed by sequencing, also had a Tm
range between 87.0–88.0°C. Of note in the sequences is
Table 1: Association between potential risk factors and HSV detected in CVL
Cofactors Present Absent Relative risk (95% CI) P-value
GUD 2/5 (40%) 25/65 (38%) 1.04 (0.34 – 3.18) 0.68
Anti HSV-2 IgG* (Kalon test) 11/27 (41%) 7/32 (22%) 1.86 (0.84 – 4.13) 0.19
HIV 3/7 (43%) 23/59 (39%) 1.1 (0.44 – 2.74) 0.83
BV 14/35 (40%) 13/35 (37%) 1.08 (0.60 – 1.95) 1.00
C. trachomatis 5/7 (71%) 22/63 (35%) 2.05 (1.15 – 3.64) 0.14
Hepatitis B 5/8 (63%) 22/54 (41%) 1.53 (0.82 – 2.87) 0.44
Candida 9/29 (31%) 18/41 (44%) 0.71 (0.37 – 1.35) 0.40
T. vaginalis 3/7 (43%) 24/63 (38%) 1.13 (0.45 – 2.80) 0.86
* Comparison with HSV-2 only. P values calculated by χ2 testVirology Journal 2005, 2:61 http://www.virologyj.com/content/2/1/61
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the high number of mutations or alternative bases con-
tained with in the probe binding area. Surprisingly probe
binding and Tm appear largely unaffected by these changes
(Figure 1). Of the 7 samples confirmed by Rotorgene, 4 of
these had no mutations in the probe binding area. The
remaining 3 samples resulted in poor quality sequencing
reactions and the results were not interpretable.
Discussion
Diagnostic methods, ranging from traditional culture and
serological detection methods, to molecular techniques,
have been described for the diagnosis of HSV. Most of
these assays, including the gold standard of viral isolation
by culture [25] are slow and prone to contamination. The
assay turn-around time for culture is 4 days as compared
to that of 4 hours for enzyme immunoassay (EIA) and 2–
4 hours for real-time PCR [26]. Viral culture diagnosis is
useful if HSV-2 is responsible for symptomatic infection
in the form of vesicles or ulcers, when live virus can usu-
ally be isolated. Success of detection further depends on
the secretion of virus during sampling. Its sensitivity relies
on the way samples are collected, transported and stored
[21]. Cell culture can only be done in laboratories with
expertise and facilities; in developing countries this facil-
ity may not be available. Accurate serological tests are
appropriate in asymptomatic cases, when viral culture and
PCR assays are largely negative [15].
Several commercially available HSV-type specific serolog-
ical assays are available, but a test such as a HSV-2 Western
blot is expensive and restricted largely to reference labora-
tories. The Kalon test, which was found to be the best
among a set of serological tests evaluated in samples from
different African cities (with sensitivity and specificity of
92.3% and 97.7% respectively) [27], tests only latent
infection and may not detect recent seroconversion [28].
DNA amplification using PCR techniques is reported to be
more sensitive than culture, and a number of studies have
used fluorescent based real time PCR techniques with
primers targeting sequences from HSV glycoprotein B,
thymidine kinase or DNA polymerase genes [21,29].
Some PCR assays require laborious post-PCR procedures
such as RFLP analysis [21], which may introduce a risk of
contamination. The high degree of sequence homology
between HSV-1 and -2 makes the design of type specific
primers challenging [30], nevertheless this has been
attempted with varying success, along with Amplification
Refractory Mutation System PCR [31].
Our assays were able to estimate HSV load and distin-
guished specific HSV-1 and -2 cervicovaginal viral secre-
tion. Amplification and typing could not be carried out in
a single PCR because, under the conditions used, insuffi-
cient specific amplicons were generated for accurate typ-
ing in a single step. This may have circumvented problems
relating to sensitivity of the HSV-1 and -2 probe relative
binding. In a single step multiplex assay mutations in the
probe binding area are reported to lead to a loss in sensi-
tivity and error in the classification of samples [24]. When
diluted amplified HSV amplicons were used for a further
typing reaction, HSV-2 was more commonly detected
than HSV-1 (70% opposed to 15%). This is concordant
with recent work that found most subjects were secreting
HSV-2 [32]. An earlier study of Gambian commercial sex
workers found that 26% of women were secreting HSV
but the study could not distinguish HSV strain types
(Aryee  et al unpublished observation). In the current
study most of the subjects secreting HSV were of age
ranging 20 – 41 years. This confirms earlier studies in
which HSV-2 was most prevalent (15 – 34 year old sub-
jects from rural Gambian communities) [12]. Thus Gam-
bian women in their twenties appear at highest risk of
HSV-2 infection. Most of the women reported in this
study were found to be secreting low levels of viral DNA
in CVL fluid. Anti HSV-2 IgG was detected in 29 out of 63
(46%) subjects which is higher than a previous Gambian
Table 2: Relationship of HSV CVL viral load with potential risk factors
Cofactor Geometric mean number of copies of virus/ml of lavage fluid
Present Absent P-values
GUD 8900 <335 0.1532
Anti HSV-2 IgG 1100* <335* 0.2976
HIV-1 infection <335 <335 0.5568
BV 400 <335 0.5020
Candida <335 <335 0.8320
Hepatitis B 400 <335 0.2480
C. trachomatis <335 <335 0.1890
T. vaginalis 17100 <335 0.0760
*Comparison done with HSV-2 only. P values calculated by non-parametric Kruskal-Wallis test.Virology Journal 2005, 2:61 http://www.virologyj.com/content/2/1/61
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Dissociation curves of amplicons used to identify HSV-1, HSV-2 and dual positive samples Figure 1
R = A/G; M = A/C; N = A/T/G/C. Control HSV-1 and -2 DNA was obtained from 2003 Quality Control Molecular Diagnostics 
2003 Proficiency panel (Block 6, Kelvin Campus, West of Scotland Science Park, Glasgow UK). The reference sequences were 
based on Blast results from NCBI. The Tm of the PCR product (146 b.p.) which was amplified during quantitation with SYBR 
Green I is shown against its complementary sequence with the SNP position marked in bold. The probe and sequence ascer-
tainment of types were in agreement. * Tm was unable to distinguish dual infection in this assay. -n.c. = not confirmed by 
sequencing.
Sample  Type
by
probe
Sequence
(reverse or minus 
strand 5’ to 3’) 
Tm of 
PCR
amplicon
(
oC)
Type
by Tm
CVL
Viral
Load
HSV-1
DNA
polymerase I 
reference
sequence
AGGGAGAGCGTgCTGAAGCAC
HSV-2
DNA
polymerase I 
reference
sequence
-----------a---------
HSV-1-g
Probe VIC 
      AGCGTgCTGAAGC
HSV-2-a
Probe FAM 
    AG-----a-------A
HSV-1
Control
1     AGAGCGTgCTGAAGCA 86.7 1
HSV-2
Control
2     -------a-------- 87.2 2
20043431  1     -------g-------M 86.6 1 <335
20043552  2     -------a-------- 87.4 2 8,742,500
20043005  2     -------a-------- 88.0 2 10,409,000
20042194  1     -------g-------R 86.9 1 <335
20043962  2     -------a-------- 87.5 2 <335
20043848  2     -------a-------- 87.5 2 345,200
20044024  1 & 2      -------r-------- 87.5 2* 3,100
20043030  2     -------a-------- 87.5 2 11,600
20042070  2     -------a-------- 87.5 2 410
20045923        1 & 2      -------r-------- 87.3 2* <335
20043691  2     -------a-------- 87.4 2 <335
20043948  2     N------a--N----- 87.5 2 <335
20047036  2     GN-----a--N----- 87.1 2 <335
20043945  2     -------a--N----- 87.3 2 <335
20042988  2     -------a-------- 88.0 2 10,000
20043687  2     N------a--TTN--- 87.5 2 <335
20044204  2     -------a--NN---- 87.1 2 <335
20042962  2     -------a-------- 87.5 2 <335
20043683  2     NN-N---a--NNT--- 87.5 2 <335
20044095  1     -------g-NNNN--- 86.9 1 <335
19985949        2     GN-----a--NCAAGC 87.5 2 <335
20044090  1 & 2      -------r-------- 87.8 2* 700
20043603  1 & 2      -------r-------- 87.0 2* <335
20044097  1 n.c 86.9 1 <335
20042480  2 n.c 87.5 2 <335
20042253  2 n.c 87.5 2 <335
20043960  2 n.c 87.5 2 340Virology Journal 2005, 2:61 http://www.virologyj.com/content/2/1/61
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study by Shaw et al [12]. The subjects for that study were
from rural Gambian communities whereas our work was
with GUM clinic attendees, whose risk of HSV-2 infection
is greater than the general population [33]. HIV has been
found to enhance the expression of HSV-2 [11]. However,
it is unlikely that co-infection with HIV is responsible for
the increased HSV-2 sero-prevalence in this study given
the low rate of HIV infection among the study subjects
and the low level of HSV secretion in HIV-1 positive sub-
jects compared to HIV-1 negative subjects.
We found anti HSV-2 IgG seropositivity correlated poorly
with HSV-2 secretion and several factors may have con-
tributed to this observation. IgG seropositivity may take
time to develop and the Kalon antibody test may not be
sensitive enough to detect early seroconversion. HSV-2
could therefore be present in secretions without
established sero-conversion. It is known that HSV-2 geni-
tal secretion is intermittent even in HSV seropositive sub-
jects so it is possible that these subjects have only recently
been exposed such that a detectable immune response has
not yet developed. The highest HSV-2 viral load in lavage
fluid was found in a seronegative subject. This result may
not be conflicting if this was a newly acquired infection
and only a primary antibody (IgM) response was stimu-
lated with levels of IgG below the sensitivity of the Kalon
test. Follow-up of subjects is required to investigate
whether subjects in which HSV secretion was identified
Dissociation curves of amplicons used to identify HSV-1, HSV-2 and dual positive samples Figure 2
Dissociation curves of amplicons used to identify HSV-1, HSV-2 and dual positive samples. No curves were observed in HSV 
negative subjects. Tm was recorded and compared with probe binding and sequence results. Collectively nine different peaks 
with Tm in the range 86.6 – 88.0°C could be observed. Three Tm representative of HSV-1, HSV-2 and dual positive samples 
confirmed by sequencing are shown with Tm indicated.
88oC
87.1oC
86.9oCVirology Journal 2005, 2:61 http://www.virologyj.com/content/2/1/61
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but were seronegative for anti HSV-2 IgG have now
seroconverted.
The data suggest that while STI such as BV, HIV, C. tracho-
matis and Hepatitis B may increase the rate and quantity
of HSV-2 secretion, these effects were not statistically sig-
nificant which is probably due to the low numbers of
women recruited for the study. The study suggested that
subjects with GUD tend to secrete more virus than those
without GUD, however, most subjects that were secreting
virus were asymptomatic and did not have GUD in line
with earlier work [16,17]. The melting temperature (Tm)
of PCR amplicons has been used to identify HSV types by
others [24,32] but these methods could not distinguish
between dual and mono specific HSV-2 infection. The use
of amplicon Tm for the assignment of a genotype has been
utilized for human SNPs using High-Resolution melting
instruments [34]. Whilst this may be applicable for the
relatively stable sequences in the human genome it may
not be a sustainable method for highly changeable viral
sequences as suggested by others.
The T to C (A/G in the reverse strand) transition that we
have identified as a distinguishing SNP appears to be
indicative of either HSV-1 or HSV-2, however, there are a
limited number of HSV sequences available in public
sequence databases to indicate that every HSV-1 or 2 will
have either T or C at that position. It has not been demon-
strated that these SNPs, PCR-RFLPs or Tm correlate with
monoclonal type specific antibody reactivity or unique
region sequence data. Further data need to be gathered to
evaluate the usefulness of these methods and their appli-
cation to population and epidemiological studies.
Conclusion
This assay was able to distinguish HSV-1 from HSV-2 and
quantify HSV genital secretion. Thirty nine percent of
women attending the GUM clinic were secreting HSV and
most of these had low viral loads in CVL fluid with no
detectable anti-HSV-2 IgG antibodies and were asympto-
matic. The presence of other STI may facilitate HSV secre-
tion but further studies with a larger sample size are
required to investigate whether the HSV type or whether
low levels of HSV genital secretion are important in the
transmission of infection.
Methods
Subjects
Seventy consecutive female subjects, attending the GUM
clinic at MRC Fajara, The Gambia from April to June 2004
were recruited. After giving informed consent, clinical
data about the subjects were recorded. This was conducted
by questionnaire and an examination for genital lesion by
the clinician/nursing officer. The study was approved and
conducted under the guidelines of The Gambian Govern-
ment and MRC Joint Ethics Committee.
Specimens
Two vaginal/cervical swab specimens were taken, after
which the cervicovaginal area was flushed with 10 ml of
phosphate buffered saline (PBS) for 1 minute and aspi-
rated into sterile tubes. Samples were kept on ice and
transported promptly to the laboratory. One ml of venous
blood was also collected and allowed to clot before cen-
trifugation at 800 × g for 10 minutes to isolate serum.
Serum was stored at -20°C until used.
Processing specimens
Cervicovaginal lavage samples were centrifuged at 1000 ×
g  for 10 min and the supernatant discarded. Cellular
materials were resuspended in 1 ml PBS and stored at -
70°C. A high vaginal swab was used to make a smear on
clean slides for Gram staining. The second swab was used
for routine microbiological analysis of STI.
DNA extraction
DNA was extracted from 200 µl of lavage cell suspension
using the QiaAmp DNA Mini kit (QIAGEN Ltd, Crawley,
UK) according to manufacturers instructions.
Selection of HSV typing single nucleotide polymorphism
A survey of HSV-1 and -2 DNA polymerase I gene
sequences available through the National Center for Bio-
technology Information (NCBI) http://
www.ncbi.nlm.nih.gov/ was conducted. Eight HSV-1
[EMBL:X03181.1], [EMBL:X04495.1], [EMBL:X04771.1],
[EMBL:X14112.1], [DDBJ:AB072389.1],
[DDBJ:AB070848.2], [DDBJ:AB070847.2], [Gen-
Bank:M10792.1] and 5 HSV-2 [GenBank:AY038367.1],
[EMBL:Z86099.2], [GenBank:M14793.1], [Gen-
Bank:M16321.1], [GenBank:AY038366.1] sequences
were identified. Following alignment, candidate SNPs
were selected in regions with no other base changes
within 20 nucleotides (i.e. within the likely probe binding
area) of the potential typing SNP. These SNPs were then
submitted for primer-probe design using either Primer
Express v2.0 (Applied Biosystems Inc, Warrington, UK) or
using the web based service of Epoch Biosciences http://
www.epochbio.com/. The optimum primer-probe design
combination was then selected for synthesis.
Detection of HSV DNA, probe typing & melting point 
determination
Quantitative PCR was performed on the ABI 5700
sequence detection system (Applied Biosystems Inc, War-
rington, UK). Duplicate 3 µl samples of extracted DNA
were added to a 22 µl PCR master mix (PCR SYBR Green
I, QIAGEN Ltd, Crawley, UK) containing 0.4 µM each
primer. The primers amplified a generic HSV 146 b.p.Virology Journal 2005, 2:61 http://www.virologyj.com/content/2/1/61
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product from the HSV DNA polymerase I gene. [forward
primer – 5'-AGCCTGTACCCCAGCATCAT-3'; reverse
primer – 5'-TGGGCCTTCACGAAGAACA-3']. Cycling
temperatures were 95°C for 15 minutes, followed by 40
cycles of 94°C for 15s, 58°C for 30s and 72°C for 30s. At
the end of amplification PCR products were subjected to
a dissociation or melting curve analysis and the Tm of the
peak was recorded. HSV PCR products were diluted one in
ten with DNase free RNase free water and probe typed
using Taqman MGB probes (Applied Biosystems, Inc,
Warrington, UK) directed against the HSV DNA polymer-
ase I gene. These probes specifically detected a C/T SNP at
position 2202 (C) for HSV-1, and 2451 (T) for HSV-2. The
probe sequences were: HSV-1 (5'-VIC-AGCGTgCT-
GAAGC-MGB-Q-3') and HSV-2 (5'-6FAM-AGAGCGTaCT-
GAAGCA-MGB-Q-3'). The probes were used in a single
tube real time PCR using the QuantiTect probe kit (QIA-
GEN Ltd, Crawley, UK) with the following cycling condi-
tions using either an Opticon 2 (GRI/MJ Research,
Braintree, UK) or Rotorgene 3000 (Corbett Research, Syd-
ney, Australia) thermal cycler: 95°C for 15 minutes, fol-
lowed by 40 cycles of 94°C for 15s, 68°C for 30s and
76°C for 30s. Fluorescence was acquired at the end of the
annealing phase. For the Rotorgene 3000 HSV typed sam-
ples, an annealing phase of 66°C for 30s was used. The
quantitative assays performed on the ABI sequence detec-
tion system included standards of 106 to 10 copies per
reaction and negative controls. These were used to gener-
ate a standard curve and calculate the copy number of the
unknown samples. HSV positive samples from the Qual-
ity Control Molecular Diagnostics 2003 Proficiency Panel
(Block 6, Kelvin Campus, West of Scotland Science Park,
Glasgow UK) were used as positive controls. All DNA
samples were tested for inhibition of PCR using bacteri-
ophage lambda (λ) DNA and primers. Briefly, test sam-
ples were 'spiked' into a PCR reaction containing
approximately 100 copies of bacteriophage λ DNA and a
primer pair directed against λ DNA. The performance of
the PCR was monitored by quantitative real-time PCR
(qPCR). The mean cycle threshold (Ct) and the standard
deviation of the controls were calculated. Samples in
which the mean Ct of the test sample fell outside the
mean Ct plus three standard deviations of the controls,
were judged to be inhibitory. Inhibitory samples were re-
extracted by a repeat of the QiaAmp Mini kit extraction
method and retested in the qPCR and inhibition assays.
HSV amplicon sequence confirmation of probe typing
One in ten dilutions of the amplified positive products
were prepared using DNase free RNase free water. A PCR
reaction was prepared by adding 6 µl of the diluted ampli-
fied positive products to 44 µl of a PCR Hotstar Taq mas-
ter mix (QIAGEN Ltd, Crawley, UK) and the HSV primers
with the addition of M13 primer sequences [HSV-M13
forward 5'-TGTAAAACGACGGCCAGTAGCCTGTAC-
CCCAGCAT-3'; HSV-M13 reverse 5'-CAG-
GAAACAGCTATGACCTGGGCCTTCACGAAGA-3'].
Cycling temperatures were the same as for the HSV real-
time quantitative assay, which used SYBR Green I, modi-
fied by the addition of 5 extra cycles and a final extension
at 72°C for 5 min. PCR DNA product and purity were
checked by electrophoresis using a 2% agarose gel. PCR
products with no primer-dimers present were purified
using Qiagen DNA mini-kits (QIAGEN Ltd, Crawley, UK).
When primer-dimers were observed specific PCR ampli-
cons were gel purified (QIAGEN Ltd, Crawley, UK). Puri-
fied PCR products were then sent to the Wellcome Trust
Centre for Human Genetics, Oxford, UK for dye-primer
Sanger sequencing on an ABI 3100 (Applied Biosystems,
Inc, Warrington, UK) capillary automated sequencer.
Detection of Chlamydia trachomatis pgp3 gene
The presence of C. trachomatis DNA was detected and
quantified by Quantitect SYBR Green I on the ABI 5700
sequence detection system using C. trachomatis pgp3
primers [forward primer 5'-GATGCGGAAAAAGCT-
TACCA-3'; reverse primer 5'-TGAATAACCCGTT-
GCATTGA-3']. These primers amplified a product of 193
b.p. from the multicopy cryptic chlamydial plasmid. PCR
cycling conditions were as recommended by the manufac-
turer annealing at 59°C for 30s and extension at 72°C for
20s for 40 cycles. Standards of 106 to 10 copies per reac-
tion of C. trachomatis pgp3 amplicons and negative con-
trols were included in each PCR reaction to generate a
standard curve and quantities of the unknown samples
estimated as before.
Serology
Serum anti HSV-2 IgG was detected using the Kalon IgG
kit (Kalon Biologicals, Ashgate, UK) and followed the
manufacturer's instructions. Detection of antibodies to
HIV-1 and HIV-2 in serum was done using Murex ICE HIV
1.2.0 ELISA Test kit (Murex, Dartford, Kent, UK). Reactive
samples were then subjected to further testing using Mon-
ospecific ELISA, Murex ICE HIV-2 for HIV-2 diagnosis and
Wellcozyme HIV Recombinant for HIV-1 (Murex, Dart-
ford, Kent, UK). Diagnoses were confirmed on a second
serum sample collected two weeks after the first sample.
For Hepatitis B the Abbott Determine™ (Abbott Laborato-
ries, Illinois, USA) HBsAg qualitative immunoassay was
used to detect Hepatitis B surface Antigen (HBsAg) in
serum samples by following the manufacturer's instruc-
tions. Serum samples from patients were also screened for
T. pallidum using MACRO-VUE Rapid plasma Reagin (BD
Biosciences, Oxford, UK) test kit and following manufac-
turer's protocol. Positive samples were confirmed using a
T. pallidum haemagglutination assay, Micro syph TP-200
(Axis-Shield Diagnostics LTD, Huntingdon, UK).Virology Journal 2005, 2:61 http://www.virologyj.com/content/2/1/61
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Microbiology
Gram stained slides were observed for the presence or
absence of Lactobacilli, BV associated organisms, Mobilun-
cus  and clue cells. Diagnosis of BV was based on the
Nugent Score. Cervical swabs were used to make smears
on slides, Gram stained and observed for Gram-negative
intracellular diplococci. Culture for the isolation of N.
gonorrhoea  was performed on Thayer Martin's medium
supplemented by vitox. Any positive cultures were tested
for oxidase and carbohydrate oxidation as confirmation
of N. gonorrhoea.
Candida, Trichomonas vaginalis and clue cells
A few drops of saline was used to make a wet preparation
of the high vaginal swab and observed under a light
microscope for the presence of Candida, T. vaginalis and
clue cells (granulated epithelial cells with Gardnerella vag-
inalis attached).
Statistical analysis
HSV viral copy numbers were log transformed before sta-
tistical analysis. Statistical analysis was carried out in EPI
Info, SPSS and Minitab. Kruskal-Wallis and χ2 tests were
used as indicated in the results.
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